ARK Investment Management LLC Buys 333,119 Shares of 908 Devices Inc. (NASDAQ:MASS)

ARK Investment Management LLC lifted its stake in shares of 908 Devices Inc. (NASDAQ:MASS) by 8.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,346,579 shares of the company’s stock after purchasing an additional 333,119 shares during the quarter. ARK Investment Management LLC owned 13.42% of 908 Devices worth $48,769,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in MASS. Point72 Middle East FZE acquired a new stake in 908 Devices during the 2nd quarter worth approximately $30,000. UBS Group AG lifted its position in shares of 908 Devices by 73.0% in the 4th quarter. UBS Group AG now owns 4,219 shares of the company’s stock worth $32,000 after purchasing an additional 1,780 shares during the period. Barclays PLC lifted its position in shares of 908 Devices by 567.3% in the 4th quarter. Barclays PLC now owns 6,186 shares of the company’s stock worth $47,000 after purchasing an additional 5,259 shares during the period. Rockefeller Capital Management L.P. acquired a new position in shares of 908 Devices during the 4th quarter valued at $48,000. Finally, Global Retirement Partners LLC acquired a new position in shares of 908 Devices during the 3rd quarter valued at $62,000. 88.06% of the stock is owned by institutional investors.

908 Devices Trading Up 5.3 %

908 Devices stock opened at $6.95 on Thursday. 908 Devices Inc. has a 12-month low of $4.85 and a 12-month high of $12.51. The firm’s fifty day moving average is $7.18 and its 200 day moving average is $7.08.

908 Devices (NASDAQ:MASS) last released its earnings results on Tuesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. The company had revenue of $14.40 million for the quarter, compared to the consensus estimate of $14.16 million. 908 Devices had a negative net margin of 72.47% and a negative return on equity of 21.09%. 908 Devices’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.31) EPS. As a group, equities research analysts predict that 908 Devices Inc. will post -1.27 EPS for the current fiscal year.

Insider Buying and Selling at 908 Devices

In other 908 Devices news, CFO Joseph H. Iv Griffith sold 5,698 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $7.00, for a total transaction of $39,886.00. Following the completion of the sale, the chief financial officer now owns 89,711 shares in the company, valued at approximately $627,977. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Joseph H. Iv Griffith sold 5,698 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $7.00, for a total value of $39,886.00. Following the completion of the sale, the chief financial officer now owns 89,711 shares in the company, valued at approximately $627,977. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin J. Knopp sold 9,071 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $7.00, for a total transaction of $63,497.00. Following the transaction, the chief executive officer now owns 411,981 shares of the company’s stock, valued at approximately $2,883,867. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,001 shares of company stock worth $139,955. 27.80% of the stock is owned by corporate insiders.

908 Devices Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.